Merck KGaA Tightens Focus With Allergopharma Sale
Allergens Business Acquired By Dermapharm For Undisclosed Sum
Executive Summary
Germany’s family-controlled big pharma, Merck KGaA, is divesting its allergens business, Allergopharma to the fast-growing Munich healthcare company, Dermapharm Holding.
You may also be interested in...
Merck KGaA Rebounds After COVID-19 Lockdowns
The coronavirus pandemic hurt the German group's healthcare division but helped the contract development and manufacturing activities of Merck's life sciences business.
Merck KGaA Sees Coronavirus Impact Subsiding In Q2
The German company is exposed to events in China across its three divisions - healthcare, life sciences and performance materials - but says that COVID-19 should only affect 2020 sales by 1%, unless a global recession happens.
P&G's Personal Health Sector Has Merck Consumer Chief As International Head
P&G names Merck KGAA consumer chief Uta Kemmerich-Keil to lead international division of personal health business as it closes on $4.2bn acquisition of German firm's consumer business. Deal closes a month after P&G announced biggest changes to organizational structure in 20 years, including combining personal care and health care into personal health and forming six global units, each headed by a CEO.